Fingers crossed the $6 million R&D rebate coming in this quarter + increased sales of higher margin Rovers + the launch of Argus and subsequent sales prevent that from happening, it is something that's been playing on my mind - dilutions are painful.
There are big things in the works though that should provide upward momentum. For 2024, clinical trials will begin for the CT scanner for stroke diagnosis, personally I'm confident MX1 will land the Australian Defence Force Land 154 contract (should be a handy couple million $ for a single contract), Argus sales will hopefully take off with gusto in the US and other allied countries, and hopefully we finally receive that CE marking in Europe for Rover which will open up sales avenues to continue the uptrend in Rover sales.
Eyes will inevitably want a piece of the growth, everything going to plan of course, I unfortunately don't have a crystal ball. Hopefully, that brings us to a point where MX1 is standing and thriving through endogenous revenue generation, rather than through outside capital.
